Fortress Biotech (FBIO) Convertible Debt (2021)

Fortress Biotech (FBIO) posted quarterly Convertible Debt of $18.1 million for Q3 2021, up 44.53% quarter-over-quarter from $12.5 million in Q2 2021.

Analysis

Fortress Biotech (FBIO) Convertible Debt (2021) Analysis & Trends

Fortress Biotech's Convertible Debt history runs 1 years deep, the most recent figure standing at $18.1 million for Q3 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	141.52 Bn	133.66 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.69 Bn	78.69 Bn	3.93 Bn
3	Argenx Se	64.63 Bn	59.45 Bn	1.37 Bn
4	Moderna	59.30 Bn	54.16 Bn	52.00 Mn
5	Revolution Medicines	44.41 Bn	44.41 Bn	-
6	BeOne Medicines	40.45 Bn	35.35 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.29 Bn	31.98 Bn	992.69 Mn
8	Royalty Pharma	28.44 Bn	27.60 Bn	-
9	Insmed	27.55 Bn	26.39 Bn	358.27 Mn
10	Fortress Biotech	86.15 Mn	-110.42 Mn	12.58 Mn

Historic Data

Download Data